Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synovis Life Technologies names new vice president of R&D
Mr Mooradian is returning to Synovis, where he was director of R&D and principal scientist from 2001 to 2004. Prior to rejoining Synovis, he served as director of
Mr Mooradian is returning to Synovis, where he was director of R&D and principal scientist from 2001 to 2004. Prior to rejoining Synovis, he served as director of
The Seven is DexCom’s second generation device designed to help people with diabetes better manage their diabetes and control their glucose levels. Terrance Gregg, president and CEO of
Previously, the National Institute for Health and Clinical Excellence (NICE) has refused to approve the kidney cancer drugs as they cost more than $70,000 a year per patient.
Prior to joining The Medicines Company, Mr Kelley held several senior management positions at Aventis Pharmaceuticals, most recently as senior vice president of global marketing and medical, where
According to the news source, the new pharmaceuticals factory will initially manufacture solubles which will be later sent to Egypt for quality assessment. The news source has quoted
The candidate vaccine is based on Vical’s DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT). hTERT is the subject of separate licensing agreement. Vijay Samant,
Mr Walsh will contribute to the development of the company’s overall business strategy and oversee finance, legal, business development and general business operations. He has spent more than
Michael McCormick, the previous CEO has resigned to pursue other interests, the company said. Most recently, Mr Lunsford served as senior vice president and president of US commercial
According to the company, its restructuring program was designed to significantly reduce costs, centralize core operations, and refocus its business strategy in specific areas where the company’s products
Mr McCaulley will have responsibility for the company’s activities in the reconstructive devices market, including global marketing and sales in the Americas. He will report to David Dvorak,